Dr. Hatim Alabbas

The placenta is a remarkable organ that plays a vital role in nourishing and supporting the development of a baby throughout pregnancy its uniquely composed of both maternal and fetal tissues and serves as a biological bridge, facilitating the exchange of oxygen, nutrients, and waste between mother and child. Due to its rich supply of stem cells from both maternal and fetal origins, the placenta has recently gained attention as a potential resource for future medical use. In response, some private cord blood banks have begun offering services to store placental tissue a development that raises several important questions: What are placental stem cells used for? How effective is tissue storage? Is it worth the investment? In this post will explores the practical applications and current scientific landscape surrounding placental tissue storage. What Is Placental Tissue Made Of? As well known the placenta comprises both fetal and maternal components the fetal side includes structures like the umbilical cord, amnion, and chorion, while the maternal side is known as the decidua basalis the maternal portion delivers oxygen and nutrients and removes waste products via the umbilical cord vessels. Although umbilical cord tissue is rich in fetal stem cells, placental tissue contains a mix of maternal and fetal cells, which introduces complexity in its isolation and potential therapeutic use. The Role of Stem Cells in Therapy Among various types of stem cells, mesenchymal stem cells (MSCs) are the most widely researched for clinical and regenerative therapies. MSCs can be harvested from several sources: adipose tissue, bone marrow, umbilical cord tissue, and placenta. However, not all MSCs are created equal. Numerous studies favor MSCs derived from umbilical cord tissue, citing advantages such as: Greater expansion capacity Lower immunogenicity Enhanced immunosuppressive properties Furthermore, umbilical cord tissue has been found to yield a significantly higher number of MSCs compared to other perinatal tissues, including the placenta. Current State of Clinical Research An analysis of the clinicaltrials.gov database reveals umbilical cord-derived MSCs are the focus of ten times more clinical trials than placental tissue-derived cells. This trend reflects the greater scientific and clinical confidence in cord tissue’s therapeutic potential. These cells have been studied for use in conditions such as: Alzheimer’s disease Multiple sclerosis Osteoarthritis Cartilage injury Spinal cord injury Stroke In contrast, placental tissue studies are limited and often group multiple perinatal tissues together, making it difficult to isolate the specific contributions of placental cells. A significant challenge with placental tissue collection is ensuring sterility, which is more readily achieved when collecting umbilical cord tissue. Regulatory and Practical Limitations The extraction of stem cells from placental tissue needs using enzymatic, chemical, or mechanical dissociation techniques where Under existing FDA regulations, any stem cell or tissue product intended for personal, or family use must be: Minimally manipulated Used for homologous purposes Placental stem cells do not meet these criteria, and are therefore classified as investigational, unlicensed drugs. As a result, they can only be used in approved clinical trials, not for routine therapeutic applications. Final Thoughts: Is Placental Tissue Storage Worth It? Despite its biological richness, placental tissue storage currently lacks strong clinical evidence to justify its routine use. The science supporting umbilical cord tissue-derived stem cells is far more advanced, with significantly more research, regulatory clarity, and therapeutic potential. While future breakthroughs may expand the role of placental cells in medicine, as of now, storing placental tissue is a speculative investment. Families considering this option should weigh the cost against the uncertain clinical benefits and consult with medical professionals for guidance.

Umbilical cord blood is a valuable source of stem cells used in transplantation and studied in advanced cellular and regenerative medicine. Cord blood is collected from the umbilical cord and placenta after birth, without harm to the mother or baby. Although it is often discarded, it contains hematopoietic stem and progenitor cells that can help rebuild the blood and immune system. For decades, cord blood has supported life-saving stem cell transplants for patients with certain blood cancers, inherited disorders, immune deficiencies and metabolic diseases. Today, it is also becoming an important platform for research into future cell-based therapies. By collecting, testing, processing and cryopreserving high-quality cord blood units, healthcare systems can preserve a biological resource that may benefit patients today and support medical innovation tomorrow. Why Cord Blood Matters The first successful cord blood transplant was performed in 1988 in a child with Fanconi anaemia. Since then, cord blood has become an established source of stem cells for selected patients who require hematopoietic stem cell transplantation. Cord blood may be used in the treatment of a range of malignant and non-malignant conditions, including: Leukaemia’s and lymphomas Bone marrow failure disorders Hemoglobinopathies Inherited metabolic diseases Severe immune deficiencies Selected genetic disorders For patients who cannot find a suitably matched adult donor, a banked cord blood unit can provide an important alternative option. Key Advantages of Cord Blood Cord blood has several features that make it different from traditional adult stem cell sources such as bone marrow or peripheral blood stem cells. 1. Ready When Needed Once a cord blood unit has been collected, tested and stored, it can be made available for future clinical use. This can reduce delays compared with searching for, contacting and preparing an adult donor. For some patients, faster access to a suitable stem cell source can be critical. 2. More Flexible Matching Cord blood transplantation can allow greater flexibility in HLA matching than many conventional donor approaches. This may be especially valuable for patients from genetically diverse backgrounds who have difficulty finding a closely matched unrelated donor. In this way, cord blood banking can support broader and more equitable access to potentially life-saving transplantation. 3. Unique Immune Properties Cord blood immune cells are less mature than those from adult donors. This gives cord blood a distinct immunological profile and may help support transplantation across certain levels of HLA mismatch. Like all transplant sources, cord blood has limitations, including cell dose and historically slower blood count recovery. However, scientific advances are helping address these challenges. Innovation Is Expanding What Cord Blood Can Do One of the most important advances in the field is ex vivo expansion, a process designed to increase the number of stem and progenitor cells available from selected cord blood units. These technologies may help address one of the traditional challenges of cord blood transplantation: providing an adequate cell dose for larger children and adults. As science advances, the potential value of a stored cord blood unit continues to evolve. The value of cord blood should not be judged only by the limitations of yesterday’s technology. Ongoing innovation is continually redefining what may be possible in transplantation, regenerative medicine and advanced cellular therapy. Beyond Stem Cell Transplantation The question is no longer only what cord blood can treat today, but what new applications may emerge through responsible research. Scientists are studying cord blood and cord-derived cellular products in areas such as regenerative medicine, immune modulation and advanced cell therapy. Research has explored potential applications in neurological conditions such as cerebral palsy, as well as cord-derived immune cells, mesenchymal stromal cells, extracellular vesicles and other novel cellular products. At the same time, scientific responsibility is essential. Website communication should clearly distinguish between established therapies, emerging treatments and experimental applications. For clear and trustworthy communication, cord blood applications can be grouped into three categories: Established clinical therapies, where cord blood is already used in defined transplant settings. Emerging treatments, where clinical evidence is developing. Experimental applications, which remain under scientific investigation. Responsible innovation requires ambition, evidence, transparency and scientific discipline. From Medical Waste to Biological Opportunity Every birth produces a unique biological resource. Without donation, banking or research programs, the placenta and umbilical cord are usually discarded after delivery. Not every cord blood unit needs to be stored, and storage should be guided by quality, clinical relevance and long-term value. The more important question is how healthcare systems can identify, collect, characterize and preserve the right biological resources for future patients and therapies. Strategic cord blood banking requires: Appropriate donor selection Quality-controlled collection and processing HLA characterization and traceability Validated cryopreservation Accreditation and long-term quality management Cord blood banking should not be viewed simply as storing a bag of blood. It is the preservation of a well-characterized biological resource that may support clinical care, research and innovation. The Cord Blood Bank of the Future Traditional cord blood banks were designed primarily to support hematopoietic stem cell transplantation. The next generation may become broader platforms for advanced biological therapies. Future cord blood banking may support: Hematopoietic stem cell transplantation Expanded stem cell products Immune cell therapies Regenerative medicine Precision medicine Translational research Cellular manufacturing Population-based biological resources For countries investing in biotechnology and advanced healthcare, this creates a strategic opportunity. High-quality cord blood infrastructure can strengthen transplant programs, improve access for genetically diverse populations, support research and help develop national capabilities in cellular and gene therapies. Not Cord Blood Versus Bone Marrow The future of medicine should not be framed as cord blood versus bone marrow, or cellular therapy versus conventional medicine. Each therapeutic platform has strengths, limitations and appropriate clinical applications. The goal is to provide the right therapy, for the right patient, at the right time. Cord blood deserves to be part of that therapeutic ecosystem. The Value of Cord Blood Is Clear More than three decades of clinical experience have shown that cord blood has real medical value. It has helped save lives, supported transplantation worldwide and opened new pathways for scientific discovery. Advances in cellular engineering, expansion technologies and regenerative medicine are creating new possibilities for how this resource may be used in the future. The responsibility now belongs to scientists, clinicians, policymakers, healthcare organizations and society to build the evidence, systems and infrastructure needed to use cord blood wisely. This means investing in quality, research, ethical communication, sustainable banking models and responsible innovation. We are not only deciding what biological material to store today. We are helping determine what therapeutic possibilities may be available tomorrow.

People often assume that leadership in healthcare is mainly about making decisions, managing budgets, supervising teams, and delivering measurable results. Those responsibilities matter, of course, but they only describe the surface of leadership. The deeper work is much more human: creating trust, giving people direction, helping teams stay grounded under pressure, and making decisions that protect both the mission and the people behind it. My experience leading a cord blood banking program has taught me that leadership is not defined by authority. It is defined by the way a leader shows up when the work is complex, the stakes are high, and people need confidence as much as they need instructions. As I progress through the Harvard Senior Leadership Program, I find myself reflecting more deeply on the lessons I have learned while leading in the field of cord blood banking. At first glance, this field may seem highly technical, centered on stem cells, laboratories, regulatory requirements, and cryogenic freezers. Yet the most important lessons I have carried with me are not only scientific or operational, but They are also leadership lessons shaped by people, purpose, patience, and the discipline required to build something that can outlast individual effort. In many ways, the work reminded me that healthcare leadership is ultimately about service. It is about serving patients we may never meet, families who place their hopes in the future, and colleagues who depend on clear direction, consistent standards, and a shared sense of meaning. Lesson one: A leader builds a system, not a position. Any organization can hire talented people, purchase advanced equipment, and write policies and procedures. These are important foundations, but they do not guarantee success. A leader’s role is to connect these pieces into a living system where people understand why the work matters, how their roles contribute to the mission, and what standards must never be compromised. Very few organizations succeed in building a culture where excellence becomes a habit rather than a campaign. Culture is built through repeated behaviors: how leaders respond to mistakes, how teams communicate risk, how quality is protected when workloads increase, and how people are encouraged to take ownership rather than simply follow instructions. A true leader builds a system that continues to function, improve, and create value even when the leader is not physically present. This requires humility, because the goal is not to make the organization dependent on one person. The goal is to develop people, clarify processes, strengthen accountability, and create a structure where good decisions can be made at every level. Lesson two: Leadership is the ability to create clarity amid uncertainty. Every day, leaders are required to make decisions with incomplete information. In healthcare, this uncertainty can be particularly challenging because decisions affect safety, resources, trust, and long-term institutional credibility. A leader cannot wait for perfect conditions before acting; instead, the leader must create enough clarity for people to move forward with confidence. Should we expand or consolidate? Should we build internally or partner externally? Should we focus on today’s needs or invest in tomorrow’s opportunities? The answer is rarely obvious. Leadership is often the ability to move forward while others are still waiting for certainty. This does not mean rushing or ignoring risk. It means listening carefully, asking the right questions, weighing the available evidence, and then communicating a direction that helps the team understand not only what we are doing, but why we are doing it. Lesson three: Strategy is choosing what not to do. One of the greatest leadership lessons I have learned is that success is not defined by the number of projects we pursue. Success depends on our ability to identify the initiatives that create the greatest long-term value and to have the discipline to focus our energy there. In leadership, saying yes is often easier because it feels active and positive. Saying no, or not yet, requires courage, judgment, and a clear understanding of priorities. Not every opportunity should be pursued, even when it appears attractive. A leader must protect the organization from distraction by distinguishing between what is interesting and what is truly strategic. Not every problem should be solved immediately, because some issues require timing, alignment, and the maturity of the system before the right solution can succeed. Not every battle should be fought, because leadership is not about proving strength in every moment. Sometimes the strongest leadership choice is to preserve trust, maintain focus, and choose the path that best serves the mission over the long term. Lesson four: Processes do not create excellence; people do. A laboratory can have outstanding technology, but without committed people, shared values, and a culture of accountability, excellence cannot be sustained. Processes are necessary, but they only become powerful when people believe in them, understand them, and apply them with care even when no one is watching. Technology can be purchased, but ownership must be developed. A leader creates an environment where people feel responsible for quality, where they speak up when something is not right, and where they understand that excellence is not a slogan but a daily standard. Commitment cannot be forced. It grows when people are respected, trusted, developed, and reminded that their work has meaning. In a sensitive field like cord blood banking, this sense of purpose is essential because every unit represents possibility, hope, and a future patient who may one day depend on the quality of what was done today. Lesson five: Great leaders think in decades, not quarters. Building a cord blood bank is not simply about collecting, processing, and storing units. It is about building a capability that may serve patients years, and sometimes decades, from now. This requires a leadership mindset that looks beyond immediate performance indicators and considers the future value of today’s decisions. It is about building trust in a system that families, clinicians, researchers, and future patients can rely on. When leaders think in decades, they become more careful with standards, more intentional with partnerships, and more patient in building capabilities that may not show immediate results but will create meaningful impact over time. That perspective changes the way leaders think. Every decision becomes an investment in the future: the people we train, the systems we design, the standards we protect, and the culture we leave behind. The work may be technical, but the responsibility is deeply human. For me, leadership is not a title, a position, or a line in an organizational chart. It is a responsibility to create direction when the path is unclear, to protect standards when pressure increases, and to help people see the meaning in the work they do every day. Leadership is the ability to transform a vision into a system, a system into a culture, and a culture into a legacy. Leading a cord blood banking program has reminded me that the most meaningful leadership is not measured only by what we achieve today, but by what we make possible for others tomorrow. What has leadership taught you about building something that lasts beyond your own presence?